A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

This is a Phase 3 study to investigate the safety and efficacy of the investigational drug, zilovertamab, when given in combination with ibrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).

Start Date01 Mar 2023

Sponsor / Collaborator

Oncternal Therapeutics, Inc.

[+1]

NCT05156905

/ TerminatedPhase 1IIT

A Phase 1b Trial Investigating Docetaxel Combined with Cirmtuzumab in Patients with Metastatic Castration Resistant Prostate Cancer

The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prostate cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men with castration resistant prostate cancer. Cirmtuzumab is a monoclonal antibody that targets the receptor called ROR1 of the non-canonical Wnt pathway and is suspected to contribute to prostate cancer growth and progression.

Start Date16 Jun 2022

Sponsor / Collaborator

University of California San Diego

NCT04501939

/ Active, not recruitingPhase 2IIT

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.

Start Date06 Aug 2020

Sponsor / Collaborator

University of California San Diego

[+1]

100 Clinical Results associated with Zilovertamab

100 Translational Medicine associated with Zilovertamab

100 Patents (Medical) associated with Zilovertamab

Literatures (Medical) associated with Zilovertamab

01 Jul 2026·Translational Cancer Research

In vitro characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity in ROR1-positive triple-negative breast cancer

Article

Author: Lin, Tian ; Zhang, Jianxing ; Huang, He ; Lin, Junshan ; Chen, Xinghe ; Xu, Yali

Background:

Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although anti-disialoganglioside 2 (GD2) monoclonal antibodies have become the standard immounotherapy for high-risk petients, antigen escape and drug resistance still lead to relapse or suboptimal responses in some cases. This study aims to develop a novel bispecific antibody (BsAb) G/R-001, which specifically binds to both GD2 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), for the treatment of NB and other tumors.

Methods:

G/R-001 BsAb (IgG1 subtype) was constructed by fusing anti-ROR1 scFv to the C-terminus of anti-GD2 heavy chain. G/R-001 was transiently expressed in HEK293 cells, purified by affinity chromatography, and characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for structure and purity. Enzyme-linked immunosorbent assay (ELISA) and flow cytometry were used to evaluate the binding capacity of G/R-001 to GD2 and ROR1. The in vitro cytotoxic activity of G/R-001 against GD2/ROR1-positive NB cells and other cancer cell lines was assessed using the lactate dehydrogenase (LDH) assay.

Results:

The theoretical molecular weight of G/R-001 was 198.82 kDa, with SDS-PAGE results showing high purity (the molecular weight of the intact antibody with glycosylation modification corresponded to approximately 248.68 kDa on non-reducing electrophoresis). Under reducing and non-reducing conditions, bands corresponding to heavy chain, light chain, and intact antibody were observed respectively. ELISA results showed that G/R-001 had a binding capacity of 12.1 nM for GD2 and 3.5 nM for hROR1. Flow cytometry further confirmed the specific binding of G/R-001 to GD2 and ROR1. LDH assay results showed that, compared with Naxitamab or Zilovertamab alone, G/R-001 exhibited significant cytotoxic activity against GD2⁺/ROR1^- LA-1, GD2^-/ROR1⁺ MDA-MB-468, and GD2⁺/ROR1⁺ MHH-NB-11 cells in a concentration-dependent manner, with cell-killing rates of 59.03%, 67.58%, and 84.50% at 100 nM, respectively. Among these, G/R-001 demonstrated the strongest cytotoxic effect against GD2⁺/ROR1⁺ MHH-NB-11 cells. G/R-001 may synergistically activates natural killer (NK) cells to potently kill NB and minimize antigen-escape risk.

Conclusions:

The G/R-001 BsAb can simultaneously bind to GD2 and ROR1, and shows significant anti-tumor activity in vitro. These results provide strong experimental evidence for the further development of G/R-001 as a novel anti-tumor therapeutic agent.

14 Jan 2026·Antibody therapeutics

A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia

Article

Author: Kipps, Thomas J ; Hasan, Md Kamrul ; Widhopf II, George

Abstract:

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is selectively expressed on chronic lymphocytic leukemia (CLL) B cells and certain cancers, but is absent from normal B cells and healthy adult tissues. GE-zilovertamab, an afucosylated anti-ROR1 IgG1 antibody, is engineered to increase FcγRIIIA binding and thereby enhance antibody-dependent cellular cytotoxicity (ADCC). Co-culture assays were performed using CLL cell lines (MEC1, MEC1-ROR1) and primary CLL cells with Jurkat-Lucia™ NFAT-CD16, NK, or peripheral blood mononuclear cell effectors. Treatments included the anti-CD20 mAb rituximab, anti-ROR1 mAbs (GE-zilovertamab, zilovertamab), and the endocytosis inhibitor prochlorperazine, and ADCC was quantified. GE-zilovertamab showed significantly higher ADCC than its parental antibody and activity that was comparable to that of rituximab. We find that the endocytosis inhibitor prochlorperazine further increased this effect. GE-zilovertamab is a promising next-generation immunotherapeutic for CLL, combining selective targeting of ROR1 with the potential to reduce therapy-induced immunodeficiency compared with anti-CD20 antibodies.Statement of Significance An afucosylated anti-receptor tyrosine kinase-like orphan receptor 1 antibody potently kills receptor tyrosine kinase-like orphan receptor 1-expressing leukemic B cells while sparing normal B cells, and this selective cytotoxicity is further enhanced by prochlorperazine. This combination has the potential to advance leukemia immunotherapy by targeting malignant cells while preserving humoral immunity, thereby addressing infection risks associated with anti-CD20 antibody regimens.

01 Jul 2025·LEUKEMIA

Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia

Article

Author: Md Kamrul Hasan ; Thomas J. Kipps ; Emanuela M. Ghia ; George F. Widhopf II

Abstract:

Matrix metalloproteinase-9 (MMP-9) facilitates the extravasation and lymphoid-tissue infiltration of chronic lymphocytic leukemia (CLL) cells. Prior studies found that high level expression of MMP-9 in CLL associates more aggressive disease. We find that circulating CLL cells that express high levels the onco-embryonic protein ROR1 express significantly higher levels of MMP-9. Stimulation of CLL cells with Wnt5a could enhance expression and the release of MMP-9 into the culture media and increase the capacity of CLL cells to invade Matrigel in a Boyden-Chamber Assay. Such effects of Wnt5a could not be inhibited by BTK inhibitors such as ibrutinib or zanubrutinib, but could be blocked by zilovertamab, a humanized mAb specific for ROR1. We found that siRNA silencing of NF-κB-p65 or use of an NF-κB inhibitor (CAS 545380-34-5) blocked the capacity of Wnt5a to induce MMP-9 or enhance the invasive capacity of treated CLL cells. Moreover, siRNA directed silencing of MMP9 or treatment with an MMP-9 inhibitor (CAS 1177749-58-4) also blocked the invasive capability of CLL cells induced by Wnt5a. We conclude that Wnt5a-induced ROR1-signaling can induce expression of MMP-9 on CLL cells through activation of NF-κB, thereby enhancing the extravasation and lymphoid-tissue infiltration required for CLL cell trafficking.

News (Medical) associated with Zilovertamab

01 Jul 2025

·www.globenewswire.com

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab. Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be eligible to receive up to $65.0 million in development, regulatory approval and sales milestone payments for the acquired products (including any future products derived from the acquired intellectual property). The development milestones consist of up to $5.0 million upon either the last patient enrolled in a pivotal clinical trial or a regulatory approval submission. The regulatory milestones consist of up to $40.0 million in connection with regulatory approvals. The sales milestone payment consists of $20.0 million upon achievement of a net sales threshold. The foregoing development and regulatory approval milestones are based on clinical trials and/or regulatory approvals in any of the following major markets: the U.S., United Kingdom, Germany, Spain, France or Italy, and Japan. The asset sale was completed on June 27, 2025, pursuant to an asset purchase agreement as of the same date. Oncternal also announced that, following the asset sale, Craig R. Jalbert has been appointed President, CEO, Treasurer, Secretary, and sole member of Oncternal’s board of directors, and Oncternal’s directors and remaining employees have resigned. Mr. Jalbert, a principal of the accounting firm Verdolino & Lowey, P.C., brings over 30 years of experience in overseeing the dissolution of companies. Mr. Jalbert will oversee the winddown of Oncternal’s operations, including any future distribution of remaining cash and future rights to any milestone-based payments. Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Oncternal’s current beliefs and expectations. Forward-looking statements include statements regarding the upfront and potential milestone consideration payable to Oncternal and plans related to, and timing of, the wind down the company. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Oncternal’s business, including, without limitation: we will be entirely dependent on Ho’ola Therapeutics for the development, regulatory approval and sales of any products subject to the asset purchase agreement; Ho’ola Therapeutics may not successfully develop any products from the asset purchase agreement due to the inherent risks in drug development as well as strategic decisions by Ho’ola Therapeutics on whether to continue any of the product programs; the timing, progress, mechanics and final results of Oncternal’s planned wind down may be delayed or cost more than expected which could delay or reduce the final payments to stockholders; and other risks described in Oncternal’s prior filings with the Securities and Exchange Commission. All forward-looking statements in this report are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Company Contact:Verdolino & Lowey, P.C.124 Washington Street, Suite 101Foxboro, MA. 02035Phone - 508-543-1720Oncternal@VLPC.com

Cell TherapyExecutive ChangeImmunotherapyAcquisition

25 Oct 2024

·www.globenewswire.com

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oct. 22, 2024 -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily (BID) oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101 (NCT05917470). Overall, fifteen patients received ONCT-534 once daily (QD) in six dosing cohorts and six patients received ONCT-534 BID in two dosing cohorts. Based on a data cut off of September 30, 2024, the BID dosing schedule was well tolerated, with no related Grade 3 or higher toxicities. One patient, who experienced a rising PSA on ONCT-534 at 160 mg BID, had a subsequent 50% reduction in PSA after four weeks of ONCT-534 at 300 mg BID, and at the same time the CAT Scan showed a 16% reduction in target lesions compared to baseline. Enumeration and biomarker analysis of circulating tumor cells (CTCs) showed promising effects on expression of androgen receptor (AR)-regulated genes, and AR nuclear translocation in six additional patients. CTC analysis also showed that some patients who did not respond to ONCT-534 had prostate cancer that had developed neuroendocrine features, which are associated with AR independent disease. “While we still believe the decision to discontinue the ONCT-534-101 clinical trial remains the correct one in the current biotechnology environment, the updated clinical results highlight the potential of ONCT-534 in prostate cancer. We believe there is value in exploring BID dosing further, as well as studying ONCT-534 in earlier lines of therapy for advanced prostate cancer,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We continue to explore strategic alternatives for our product candidates, including ONCT-534, ONCT-808, zilovertamab and ONCT-216 in an ongoing effort to maximize value to our shareholders.” Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. More information on our company and programs is available at https://oncternal.com/. ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) with demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR mutation and aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor pathway inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. It was investigated in Study ONCT-534-101 (NCT05917470) for the treatment of patients with mCRPC who are resistant to current AR pathway inhibitors. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced compared with currently approved CAR T products. It was investigated in Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. Zilovertamab (previously called cirmtuzumab and UC-961) is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 48 months in CLL patients whose tumors harbored del(17p)/p53 mutation, a population underserved by current treatment options. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zilovertamab for the treatment of CLL and MCL. The results of an investigator-sponsored, Phase 1b clinical trial of zilovertamab in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer were recently published (Shatsky 2023). Zilovertamab was evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (NCT05156905), and an investigator-initiated Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory (R/R) CLL (NCT04501939). ONCT-216 (previously called TK216) is an investigational targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins including fusion proteins. Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma. ETS-related translocations or overexpression are also found in many other tumors such as acute myeloid leukemia (AML), diffuse large B cell lymphoma (DLBCL), and prostate cancer. In preclinical models, ONCT-216 was observed to bind to EWS-FLI1, blocking the interaction between this fusion protein and other transcriptome proteins such as RNA helicase A, leading to tumor cell apoptosis and inhibiting tumor growth in animal models. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Status to ONCT-216 for the treatment of Ewing sarcoma. The results of a Phase 1/ 2 clinical trial of ONCT-216 in patients with Ewing sarcoma (NCT02657005) were recently published (Myers 2024). The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultOrphan DrugFast TrackImmunotherapy

13 Sep 2024

·endpts.com

Oncternal stops cancer trials and begins search for future business options

After disappointing efficacy data and a patient death, Oncternal Therapeutics is discontinuing two trials and looking for strategic alternatives. The San Diego company said it would end a Phase 1 trial investigating ONCT-534, a dual-action androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer. In the early-stage study, the drug did not show clinically meaningful improvements in disease like prostate-specific antigen levels, the company said Thursday. Its other candidate, the ROR1-targeting autologous CAR-T dubbed ONCT-808, showed anti-tumor activity at all doses in aggressive B cell lymphoma. That included a complete metabolic response lasting eight months and long-term persistence of the CAR-T cells. While the asset also came with “expected treatment-emergent adverse events” for a CAR-T therapy, a patient died from “complications of shock” at the highest dose. Based on these results, the company said it would stop development, cut its workforce and look for other options, including asset sales, licensing or a merger or acquisition. “In light of these data and the challenging financing environment, we intend to explore strategic options with the hope of advancing and realizing value from our pipeline including ONCT-534, ONCT-808, zilovertamab and ONCT-216,” president and CEO James Breitmeyer said in a statement. Oncternal’s stock $ONCT dipped nearly 3% on Friday morning, trading at $1.65. Zilovertamab is a monoclonal antibody designed to inhibit the function of ROR1. It is in separate investigator-led studies in metastatic castration-resistant prostate cancer and chronic lymphocytic leukemia . ONCT-216 is currently not listed in the company’s R&D pipeline . In April 2022, it discontinued recruiting subjects in a Phase 1/2 trial in Ewing sarcoma to “reallocate resources.”

Cell TherapyImmunotherapy

100 Deals associated with Zilovertamab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Zilovertamab	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Lymphoma	Phase 3	-	Oncternal Therapeutics, Inc.	01 Mar 2023
Mantle cell lymphoma refractory	Phase 3	-	Oncternal Therapeutics, Inc.	01 Mar 2023
Mantle-Cell Lymphoma	Phase 3	United States	Oncternal Therapeutics, Inc.	04 Jan 2022
Mantle-Cell Lymphoma	Phase 3	United States	University of California	04 Jan 2022
Chronic Lymphocytic Leukemia	Phase 2	United States	University of California San Diego	03 Jan 2018
Marginal Zone B-Cell Lymphoma	Phase 2	United States	Oncternal Therapeutics, Inc.	03 Jan 2018
Marginal Zone B-Cell Lymphoma	Phase 2	United States	University of California San Diego	03 Jan 2018
Small Lymphocytic Lymphoma	Phase 2	United States	Oncternal Therapeutics, Inc.	03 Jan 2018
Small Lymphocytic Lymphoma	Phase 2	United States	University of California San Diego	03 Jan 2018
Castration-Resistant Prostatic Cancer	Phase 1	United States	Oncternal Therapeutics, Inc.	14 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02776917 (phase 1b study of zilovertamab, CTgov)	Phase 1	Locally Advanced Unresectable Breast Carcinoma	23	Cirmtuzumab+Paclitaxel	odlredgoom = gllirtwuaj plrdkwgrly (ospdkkczvp, hatltctzpn - exudyrijag) View more	-	07 Aug 2025
NCT03088878 (CIRM-0001, GlobeNewswire) Manual	Phase 1/2	Mantle-Cell Lymphoma \| Chronic Lymphocytic Leukemia \| Marginal Zone B-Cell Lymphoma TP53	-	Zilovertamab (CLL)	iueuxzkzya(gauymovtsq) = gqoyhhmmno fgidweaico (xvzigjlbye )	Positive	29 Feb 2024
NCT02776917 (phase 1b study of zilovertamab, Pubmed \| Breast Cancer Res)	Phase 1	Metastatic HER2-Negative Breast Carcinoma ROR1	16	Zilovertamab 600 mg	xxzutdommo(pbemiwoxbh) = vvvxrrqzee fqhnbqqdmn (jzyzybjref ) View more	Positive	26 Feb 2024
	Phase 1	Metastatic HER2-Negative Breast Carcinoma ROR1	16	Paclitaxel 80 mg/m2	xxzutdommo(pbemiwoxbh) = xceclatfzc fqhnbqqdmn (jzyzybjref ) View more	Positive	26 Feb 2024
ICML2023	Phase 1/2	Mantle-Cell Lymphoma \| Chronic Lymphocytic Leukemia \| Marginal Zone B-Cell Lymphoma TP53 mut/del(17p)	99	Zilovertamab 600 mg IV q4wks + Ibrutinib 420 mg (CLL) or 560 mg (MCL) daily	rqrzoyvsce(cafomfgyvs) = 9.4% of all pts treated stmkbgojij (flnrdaawuq ) View more	Positive	09 Jun 2023
NCT03088878 (ASCO2022)	Phase 1/2	Mantle-Cell Lymphoma \| Chronic Lymphocytic Leukemia	102	Zilovertamab	cqwtonuccd(albaynndql) = hoxudzrlej becbkpqviu (yelwjioipl ) View more	-	02 Jun 2022
NCT03088878 (ASCO2021)	Phase 1/2	Mantle-Cell Lymphoma \| Chronic Lymphocytic Leukemia	102	Cirmtuzumab	qrfsdwfpuh(cgrihfmxhl) = uykudmtjcx nmsbwizyvt (gdwgbaybow ) View more	-	28 May 2021
NCT02222688 (CTgov)	Phase 1	Chronic Lymphocytic Leukemia \| Chronic lymphocytic leukaemia refractory	26	cirmtuzumab (Cirmtuzumab 0.015 - 0.03 mg/kg)	vyitlvmfhm = cyyakggtee rzqskkmuze (neiisrjpzn, kgaribpknk - bvpjlzkgfk) View more	-	13 Aug 2020
NCT02222688 (CTgov)	Phase 1		26	cirmtuzumab (Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg)	vyitlvmfhm = fodmtovjfm rzqskkmuze (neiisrjpzn, csnyzixgwt - feataxlidx) View more	-	13 Aug 2020
NCT03088878 (ASCO2020)	Phase 2	Mantle-Cell Lymphoma \| Chronic Lymphocytic Leukemia	46	Cirmtuzumab + Ibrutinib	gpdaqkssas(hmboslicha) = only grade 1/ 2 AEs were reported as possibly related to Cirm alone, whereas the safety profile attributed to Ibr or Ibr / Cirm was similar to published data, with no new or unexpected events kjtzhnbitc (trvjyjnzfs )	Positive	25 May 2020
NCT02776917 (AACR2020) Manual	Phase 1	Locally advanced breast cancer HER2 Positive \| ROR1 Positive	15	paclitaxel +cirmtuzumab	frprlfaffr(zploergkzv) = none xbxpyztecy (qkjxaqalyd ) View more	Positive	15 Feb 2020
ASCO2019	Phase 1/2	Chronic Lymphocytic Leukemia	-	Cirmtuzumab	gypoutkbla(qhgygzkwwh) = 1 atrial fibrillation event eggjrrdhsr (lpzdpjkjvt ) View more	Positive	26 May 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis